Drug Search Results
More Filters [+]

Zofin

Alternative Names: zofin, Organicell Flow, Organicell
Latest Update: 2024-10-01
Latest Update Note: News Article

Product Description

Organicell Regenerative Medicine is developing Zofin as a treatment for COVID-19, COPD, and Osteoarthritis. (Sourced from: https://organicell.com/zofin-2/)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Pakistan

Approved Indications: None

Known Adverse Events: None

Company: Organicell Regenerative Medicine
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zofin

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Acute Lung Injury|Acute Respiratory Distress Syndrome|COVID-19|Respiratory Distress Syndrome, Newborn

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT05228899

P2

Completed

COVID-19

2023-10-01

25%

NCT04384445

P2

Completed

COVID-19|Acute Lung Injury|Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn

2023-07-01

35%

Recent News Events